Dianthus Therapeutics Inc (NASDAQ: DNTH) is 177.21% higher on its value in year-to-date trading and has touched a low of $6.58 and a high of $33.77 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The DNTH stock was last observed hovering at around $28.77 in the last trading session, with the day’s gains setting it 0.06%.
Currently trading at $28.83, the stock is 2.64% and 4.27% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.16 million and changing 0.21% at the moment leaves the stock 31.66% off its SMA200. DNTH registered 134.31% gain for a year compared to 6-month gain of 11.96%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 2.93% loss in the last 1 month and extending the period to 3 months gives it a 33.41%, and is 1.87% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.33% over the week and 7.22% over the month.
Dianthus Therapeutics Inc (DNTH) has around 53 employees, a market worth around $846.16M and $4.12M in sales. Profit margin for the company is -1376.42%. Distance from 52-week low is 338.15% and -14.63% from its 52-week high. The company has generated returns on investments over the last 12 months (-15.82%).
The EPS is expected to grow by 73.22% this year.
Dianthus Therapeutics Inc (DNTH) Top Institutional Holders
110.0 institutions hold shares in Dianthus Therapeutics Inc (DNTH), with institutional investors hold 107.46% of the company’s shares. The shares outstanding are 29.35M, and float is at 20.07M with Short Float at 20.23%. Institutions hold 101.95% of the Float.
Dianthus Therapeutics Inc (DNTH) Insider Activity
The most recent transaction is an insider purchase by Fairmount Funds Management LLC,the company’sDirector. SEC filings show that Fairmount Funds Management LLC bought 24,670 shares of the company’s common stock on Sep 29 ’23 at a price of $13.63 per share for a total of $0.34 million. Following the purchase, the insider now owns 1.93 million shares.
Dianthus Therapeutics Inc disclosed in a document filed with the SEC on Sep 26 ’23 that Fairmount Funds Management LLC (Director) bought a total of 30,000 shares of the company’s common stock. The trade occurred on Sep 26 ’23 and was made at $13.15 per share for $0.39 million. Following the transaction, the insider now directly holds 1.9 million shares of the DNTH stock.
Still, SEC filings show that on Sep 22 ’23, Randhawa Simrat (Chief Medical Officer) acquired 2,000 shares at an average price of $13.20 for $26400.0. The insider now directly holds 4,000 shares of Dianthus Therapeutics Inc (DNTH).
